Adithya Cattamanchi
Overview
Explore the profile of Adithya Cattamanchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
4346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nalugwa T, Annerstedt K, Nabwire S, West N, Kadota J, Atkins S, et al.
Int J Equity Health
. 2025 Mar;
24(1):73.
PMID: 40087654
Background: Social and structural determinants of health (SDoH) are associated with tuberculosis (TB) outcomes but often unaddressed in TB care programs. We sought to describe the mechanism by which SDoH...
2.
Izudi J, Bajunirwe F, Cattamanchi A
BMJ Public Health
. 2025 Feb;
2(2):e001136.
PMID: 40018619
Introduction: Multimonth dispensing of antituberculosis (TB) drugs reduces frequent visits and costs associated with longer travel distances to a TB clinic. We will evaluate the effectiveness of multimonth dispensing of...
3.
Jaganath D, Nabeta P, Nicol M, Castro R, Wambi P, Zar H, et al.
medRxiv
. 2025 Jan;
PMID: 39763536
Background: Centrifuge-free processing methods support stool Xpert Ultra testing for childhood tuberculosis (TB), but there are limited data on their accuracy, acceptability and usability. Methods: We conducted a prospective evaluation...
4.
Fossati A, Wambi P, Jaganath D, Calderon R, Castro R, Mohapatra A, et al.
medRxiv
. 2024 Dec;
PMID: 39677468
Failure to rapidly diagnose tuberculosis disease (TB) and initiate treatment is a driving factor of TB as a leading cause of death in children. Current TB diagnostic assays have poor...
5.
Katamba A, Mochizuki T, Nalugwa T, Nantale M, Oyuku D, Nabwire S, et al.
EClinicalMedicine
. 2024 Dec;
78:102953.
PMID: 39659443
Background: Rapid diagnosis of tuberculosis (TB) is important for improving outcomes and reducing transmission. Previous studies assessing the impact of Xpert MTB/RIF (Xpert), a molecular assay that provides results within...
6.
C-Reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study
Derendinger B, Mochizuki T, Marcelo D, Shankar D, Mangeni W, Nguyen H, et al.
Am J Respir Crit Care Med
. 2024 Dec;
211(3):499-506.
PMID: 39642368
C-reactive protein (CRP)-based tuberculosis (TB) screening is recommended for people with HIV. However, its performance among people without HIV and in diverse settings is unknown. In a multicountry study, we...
7.
Aschmann H, Musinguzi A, Kadota J, Namale C, Kakeeto J, Nakimuli J, et al.
J Int AIDS Soc
. 2024 Nov;
27(12):e26390.
PMID: 39587885
Introduction: Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens...
8.
Kadota J, Musinguzi A, Aschmann H, Akello L, Welishe F, Nakimuli J, et al.
Open Forum Infect Dis
. 2024 Nov;
11(11):ofae667.
PMID: 39582503
Background: Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and rifapentine (3HP), are increasingly used in high-TB-burden countries. Despite established safety and tolerability in efficacy trials, 3HP-related adverse...
9.
Crowder R, Thangakunam B, Andama A, Christopher D, Dalay V, Nwamba W, et al.
Clin Infect Dis
. 2024 Nov;
PMID: 39509711
Background: Accessible, accurate screening tests are necessary to advance tuberculosis (TB) case finding and early detection in high-burden countries. Methods: We prospectively screened adults with ≥2 weeks of cough at...
10.
Musinguzi A, Kasidi J, Kadota J, Welishe F, Nakitende A, Akello L, et al.
PLOS Glob Public Health
. 2024 Oct;
4(10):e0003347.
PMID: 39446746
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify...